PRT4165 is a potent inhibitor of PRC1 (polycomb-repressive complex 1)-mediated histone H2A ubiquitylation in vivo and in vitro. PRT4165 inhibits the in vitro histone H2A E3 ubiquitin ligase activity of PRC1 components RING1, RNF2, and a BMI1/RNF2 complex. PRT4165 also inhibits DNA double-strand breaks induced ubiquitylation of histone H2AX.
| Molecular Weight | 235.24 |
| Formula | C15H9NO2 |
| CAS Number | 31083-55-3 |
| Form | Solid |
| Solubility (25°C) | DMSO: 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related E1/E2/E3 Enzyme Products |
|---|
| NX-1607
NX-1607 is an oral, small molecule inhibitor of casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) that has been shown to enhance antigen recall, reduce T cell exhaustion and increase cytokine production upon T cell receptor stimulation, overcoming suppressive signals from the tumor microenvironment (TME). |
| SENP1-IN-1
SENP1-IN-1 is a specific deSUMOylation protease 1 (SENP1) inhibitor. SENP1-IN-1 can be used for tumor radiosensitivity enhancement. |
| TRAF6 peptide
TRAF6 peptide is a specific TRAF6-p62 inhibitor. |
| LTP001
LTP001 is a SMURF1 antagonist that can be used in studies related to idiopathic pulmonary fibrosis (IPF). |
| HECT E3-IN-1
HECT E3-IN-1 is a HECT E3 ligase inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
